Description of the clinical case of the use of the apremilast in a patient with an oncological history

Background. Apremilast is the first representative of low-molecular targeted disease-modifying anti-inflammatory drugs for the treatment of psoriasis and psoriatic arthritis (PsA). Apremilast is selective phosphodiesterase-4 (PDE-4) inhibitor. Obviously, in the future, apremilast will occupy an important place in the treatment of psoriasis and PsA due to its oral form, proven effectiveness in relation to various forms of psoriasis and a favorable safety profile. Description of the clinical case. An example of the successful use of amremilast therapy in the treatment of a patient with vulgar psoriasis, PsA and an oncological history (breast cancer) is presented. A fast and stable normalization of PASI parameters with the disappearance of skin elements was achieved. The treatment was well tolerated; no adverse events were observed during therapy. Conclusion. It can be concluded that the use of the PDE-4 inhibitor apremilast allows to control psoriasis and improve the quality of life of patients, including with concomitant pathology.

psoriasis, psoriatic arthritis, apremilast, oncological diseases